From a choleretic to an immunomodulator: Historical review of ursodeoxycholic acid as a medicament

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 6, 1998, Pages 659-664

  Makino, Isao ^a   Tanaka, Hirotoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLERETIC AGENT; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CHOLELITHIASIS; CHOLESTEROL STONE; CHRONIC HEPATITIS; DRUG EFFECT; DRUG ISOLATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOMODULATION; LIVER FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031723929     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00707.x     Document Type: Review

References (69)

1. Hammarsten O. Untersuchungen uber die Gallen einiger Polarthiere. I. Uber die Galle des Eisbaren. I Abschnitt. Hoppe-Soyler's. Z. Physiol. Chem. 1901; 32: 435-66.
2. Hammarsten O. Untersuchungen uber die Gallen einiger Polarthiere. I. Uber die Galle des Eisbaren. II Abschnitt. Hoppe-Seyler's. Z. Physiol. Chem. 1902; 36: 525-55.
3. Shoda M. Uber die Ursodeoxycholsaure aus Barengallen und ihre physiologische Wirkung. J. Biochem. 1927; 7: 505-17.
4. Iwasaki T. Uber the Konstitution der ursodesoxycholsaure. Z. Physiol. Chem. 1936; 244: 181-93.
5. Kanazawa T, Shimazaki A, Sato T et al. Studies on the synthesis of ursodeoxycholic acid. Jpn. J. Chem. 1955; 76: 297-301.
6. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N. Engl. J. Med. 1972; 286: 1-8.
7. Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Jpn J. Gastroenterol. 1975; 72: 690-702.
8. Nakagawa S, Makino I, Ishizaki K, Dohi I. Dissolution of cholesterol gallstones by ursodeoxycholic acid. Lancet 1977; 2: 367-9.
9. Sugata F, Shimizu M. Retrospective studies on gallstone disappearance. Jpn. J. Gastroenterol. 1974; 71: 75-80.
10. Bachrach W, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig. Dis. Sci. 1982; 27: 737-61.
11. Bachrach W, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig. Dis. Sci. 1982; 27: 833-56.
12. Schoenfield LJ, Lachin JM, The Steering committee, The National Cooperative Gallstone Study Group. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones; the national cooperative gallstone study. A controlled trial of efficacy and safety. Ann. Intern. Med. 1981; 95: 257-82.
13. Igimi H, Carey MC. Cholesterol gallstone dissolution in bile; dissolution kinetics of crystalline (anhydrate and mono hydrate) cholesterol with chenodeoxycholate, ursodeoxycholate, and their glycine and taurine conjugates. J. Lipid Res. 1981; 22: 254-70.
14. Igimi H, Asakawa S, Watanabe D, Shimura H. Liquid crystal formation in ursodeoxycholate-rich human gallbladder bile. Gastroenterology Jpn. 1983; 18: 93-7.
15. Igimi H, Nishijima S, Shimura H. The developmental process from micelle to liquid chrystal in the ursodeoxycholate, phosphatidylcholine and cholesterol solution. J. Phar. Dyn. 1983; 6: 267-71.
16. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man. J. Clin. Invest. 1968; 47: 1043-52.
17. Carey M, Small DM. The physical chemistry of cholesterol by solubility in bile; relationship to gallstone formation and dissolution in man. J. Clin. Invest. 1978; 61: 998-1026.
18. Ichida F. The experience of ursodeoxycholic acid administration for patients with chronic hepatitis. Sindan-to-tiryou. 1961; 49: 388-92 (in Japanese).
19. Wakahara T, Yoshida H, Bandou T et al. Effect of urso-san on chronic liver diseases. Sindan-to-tiryou. 1975; 63: 1070-3 (in Japanese).
20. Yamanaka M, Ohtou M, Obata H et al. Effect of ursodeoxycholic acid on chronic hepatitis; a double blind trial. Sindan-to-tiryou. 1976; 64: 2150-7 (in Japanese).
21. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow up; a pilot study. Dig. Dis. Sci. 1985; 30: 642-9.
22. Podda M, Ghezzi C, Battezzati PM et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig. Dis. Sci. 1989; 34 (Suppl): S59-5.
23. Ballentani S, Tabarroni G, Barchi T et al. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hyper-transaminasemia. J. Hepatol. 1989; 8: 7-12.
24. Guslandi M. Treatment of chronic liver disease with ursodeoxycholic acid. J. Int. Med. Res. 1990; 18: 497-505.
25. Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Podda A. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990; 98: 1044-50.
26. Rolandi E, Franceschini R, Caraldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur. J. Clin. Pharmacol. 1991; 40: 473-6.
27. De Caestecker JS, Jazrawi RP, Petroni ML, Northfield TC. Ursodeoxycholic acid in chronic liver disease. Dig. Dis. Sci. 1991; 36: 1061-5.
28. Crosignani A, Battezzati PM, Setchell DR et al. Effect of ursodeoxycholic acid on serum liver enzyme and bile acid metabolism in chronic active hepatitis; a dose-response study. Hepatology 1991; 13: 339-44.
29. Dumont M, Eringer S, Uchman S. Hypercholeresis induced by ursodeoxycholic acid in the rat; possible role of bicarbonate transport. Gastroenterology 1980; 79: 82-9.
30. Kitani K, Kanai S. Biliary transport maximum of tauroursodeoxycholate is twice as high as that of taurocholate in the rat. Life Sci 1981; 29: 269-75.
31. Kitani K, Kanai S. Tauroursodeoxycholate prevents taurocholate increased cholestasis. Life Sci. 1982; 90: 515-23.
32. Kitani K, Ohta M, Kanai S. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat. Am. J. Physiol. 1985; 248: G407-17.
33. Tomoda T, Moriwaki H, Onishi H et al. Therapeutic effect of ursodeoxycholic acid on sulpyrine-induced intrahepatic cholestasis; a case report. Jpn. J. Gastroenterol. 1984; 81: 2821-5 (in Japanese).
34. Poupon RE, Cheretien Y, Popon R, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1: 834-6.
35. Roda E, Mazzella G, Bazzoli F et al. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis. Dig. Dis. Sci. 1989; 34: S52-8.
36. Matuzaki Y, Tanaka N, Osuga T et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 1990; 85: 15-23.
37. Fukui H, Yamao J, Yoshitani M, Masumura Y, Tsujii T. Ursodeoxycholic acid therapy for primary biliary cirrhosis. In: Inoue K, ed. Primary biliary cirrhosis: pathophysiology, treatment and prognosis. Tokyo: Herusu Publishing Company, 1994; 147-58.
38. Floreani A, Zappala F, Mazzetto M, Naccarato R, Plebani M, Chiramonte M. Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of diseases. Dis. Dis. Sci. 1994; 39: 9-14.
39. Poupon RE, Balkau B, Eschwege E, Poupon R, The UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med. 1991; 324: 1548-54.
40. Oda H, Toda G, Ikeda Y et al. A multi-center double blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn. 1990; 25: 774-80.
41. Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N. Engl. J. Med. 1994; 330: 1342-7.
42. Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-90.
43. Heathcote EJ, Cauch-Dudek K, Walker V et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 1149-56.
44. Lindor KD, Dickson ER, Jorgensen RA et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis; the results of a pilot study. Hepatology 1995; 22: 1158-62.
45. Ikeda T, Tozuka S, Noguchi O et al. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J. Hepatol. 1996; 24: 88-94.
46. Tanaka S, Ito Y, Yokosaka O et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
47. Kiso S, Kawata S, Imai Y, Tamura S, Inui Y, Ito N. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. J. Gastroenterol. 1996; 31: 75-80.
48. Boucher E, Jouanolle H, Andre P et al. Interferon and ursodeoxycholic acid combination therapy in the treatment of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322-7.
49. Angelico M, Gandin C, Pescarmona E et al. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone treatment of chronic hepatitis C: A randomized clinical trial with long-term follow-up. Am. J. Gastroenterol. 1995; 90: 263-9.
50. Tanaka K, Kondo M, Sakasguchi T et al. Efficacy of ursodeoxycholic acid in combination with interferon-α in treating chronic hepatitis C: Results of long-term followup trial. J. Gastroenterol. Hepatol. 1996; 11: 1155-60.
51. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis; placebo-controlled trial. Hepatology 1992; 16: 707-14.
52. Stiehl A, Walker S, Stieh L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis, A 3-year pilot study with a placebo-controlled study period. J. Hepatol. 1994; 20: 57-64.
53. Mima S, Sekiya T, Kanagawa H et al. Effect of ursodeoxycholic acid on autoimmune hepatitis. Acta Hepatologica Japonica 1992; 34: 849-50.
54. Nakamura K, Akiyama K, Makino I. Effect of long term ursodeoxycholic acid treatment on serum liver enzyme and serum bile acid metabolism in chronic hepatitis. Jpn. J. Gastroenterol. 1995; 92: 62-71.
55. Toda G, Zeniya M, Watanabe F et al. Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. J. Hepatol. 1997; 26: 1207-12.
56. Tsujii T, Yoshikawa M. Immunomodulation by bile acids. In: Makino I, ed. Bile acid and digestive disease: recent advance. Tokyo: Herusu Publishing Company. 1995; 11-14.
57. Gianni L, Di Padova F, Zuin M, Podda M. Bile acid induced lymphoproliferative response to phytohaemagglutinin and pokeweed mitogen; an in vitro study. Gastroenterology 1980; 78: 231-5.
58. Keane RM, Gudacz TR, Munster AM, Birmingham W, Winchurch RA. Impairment of human lymphocyte function by bile salts. Surgery 1984; 95: 439-43.
59. Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993; 18: 165-72.
60. Yoshikawa M, Tsujii T, Matsumura K et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16: 358-64.
61. Terasaki S, Nakamura Y, Ogino H, Unoura M, Kabayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am. J. Gastroenterol. 1991; 86: 1194-9.
62. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-15.
63. Hirano F, Tanaka H, Makino I. Regulation of the major histocompatibility complex class I mRNA expression by bile acids in cultured human hepatoma cells. Biochem. Biophys Res. Commun. 1993; 195: 1408-14.
64. Hirano F, Tanaka H, Makino Y et al. Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression. J. Gastroenterol. 1996; 31: 55-60.
65. Tanaka H, Makino Y, Miura T et al. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. J. Immunol. 1996; 156: 1601-8.
66. Tanaka H, Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 1992; 188: 942-8.
67. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-95.
68. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44.
69. Tanaka H, Makino I. Bile acids and immune regulation. Jpn. J. Gastroenterol. 1996; 93: 693-9.